JCR Pharmaceuticals starts construction of new biopharmaceutical plant

JCR Pharmaceuticals Co., Ltd. (TSE: 4552) has commenced construction of a new drug product plant within the Kobe Science Park Center, adjacent to its existing API plant that began operations in November 2022. The new plant is partially funded by subsidies from the Ministry of Economy, Trade and Industry's "Project for Establishing Biopharmaceutical Manufacturing Sites to Strengthen Vaccine Production." This initiative aims to establish an integrated manufacturing system for vaccines in preparation for potential pandemic emergencies.